Verrica Pharmaceuticals Inc. (VRCA): Long-Term Debt
$0
As of 2025-12-31
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $30.98M | -27.7% | 2026-03-11, Balance as of period end |
| 2023-12-31 | $42.87M | n/a | 2025-03-11, Balance as of period end |
| 2022-12-31 | $0 | n/a | 2024-02-29, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $0 | -100.0% |
| Verastem, Inc. (VSTM) | 2024-12-31 | $40.72M | +1.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $45.00M | 0.0% |
| Journey Medical Corp (DERM) | 2025-12-31 | $25.28M | +1.6% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $47.21M | n/a |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $52.42M | -9.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $9.70M | +1.9% |
| uniQure N.V. (QURE) | 2025-12-31 | $71.92M | +8.9% |
| Eton Pharmaceuticals, Inc. (ETON) | 2024-12-31 | $29.81M | n/a |
Compare VRCA, VSTM, AQST, DERM side by side · Screen every company in Pharmaceutical Preparations ↗